verapamil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, verapamil derivatives 2815 52-53-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • verapamil
  • RS-Verapamil
  • (+/-)-Verapamil
  • verapamil hydrochloride
  • verapamil HCl
A calcium channel blocker that is a class IV anti-arrhythmia agent.
  • Molecular weight: 454.61
  • Formula: C27H38N2O4
  • CLOGP: 4.47
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 63.95
  • ALOGS: -5.06
  • ROTB: 13

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.24 g O
0.24 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.75 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 22 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.09 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 12, 1981 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1072.32 10.58 909 44612 137292 53166253
Bradycardia 474.50 10.58 430 45091 70626 53232919
Toxicity to various agents 294.62 10.58 606 44915 218992 53084553
Atrioventricular block complete 286.68 10.58 139 45382 7876 53295669
Cardiogenic shock 276.04 10.58 177 45344 17305 53286240
Hypotension 258.60 10.58 628 44893 253448 53050097
Drug interaction 201.84 10.58 522 44999 218807 53084738
Metabolic acidosis 167.16 10.58 193 45328 42049 53261496
Rheumatoid arthritis 143.57 10.58 45 45476 314486 52989059
Nodal rhythm 140.98 10.58 54 45467 1706 53301839
Atrioventricular block 137.33 10.58 82 45439 7058 53296487
Overdose 130.95 10.58 286 45235 107450 53196095
Intentional overdose 124.12 10.58 213 45308 66992 53236553
Anuria 102.51 10.58 85 45436 12355 53291190
Atrioventricular block first degree 95.37 10.58 63 45458 6472 53297073
Nodal arrhythmia 93.51 10.58 37 45484 1277 53302268
Acute respiratory distress syndrome 91.25 10.58 106 45415 23226 53280319
Cardiac arrest 91.17 10.58 228 45293 93439 53210106
Sinus bradycardia 90.74 10.58 85 45436 14516 53289029
Shock 83.68 10.58 101 45420 23038 53280507
Joint swelling 71.83 10.58 57 45464 234581 53068964
Glossodynia 69.40 10.58 4 45517 100287 53203258
Atrial fibrillation 69.07 10.58 231 45290 111421 53192124
Systemic lupus erythematosus 66.71 10.58 13 45508 125401 53178144
Contraindicated product administered 62.50 10.58 19 45502 135610 53167935
Suicide attempt 60.19 10.58 145 45376 58023 53245522
Infusion related reaction 60.01 10.58 29 45492 155928 53147617
Hand deformity 59.90 10.58 3 45518 84846 53218699
Poisoning 59.37 10.58 66 45455 13784 53289761
Electrocardiogram QT prolonged 58.79 10.58 141 45380 56262 53247283
Supraventricular tachycardia 57.55 10.58 66 45455 14259 53289286
Atrioventricular block second degree 57.54 10.58 38 45483 3901 53299644
Rash 56.99 10.58 193 45328 445998 52857547
Cardiac failure congestive 55.67 10.58 190 45331 92567 53210978
Electrocardiogram QRS complex prolonged 53.15 10.58 42 45479 5700 53297845
Neovascularisation 52.35 10.58 20 45501 627 53302918
Alopecia 51.71 10.58 75 45446 234508 53069037
Arthropathy 50.44 10.58 29 45492 141424 53162121
Rhabdomyolysis 48.15 10.58 112 45409 43811 53259734
Cerebrovascular accident 45.42 10.58 194 45327 104980 53198565
Drug intolerance 44.99 10.58 66 45455 205427 53098118
Lower respiratory tract infection 43.27 10.58 12 45509 90969 53212576
Pericarditis 43.26 10.58 3 45518 64403 53239142
Drug ineffective 42.48 10.58 470 45051 816775 52486770
Pain 41.56 10.58 313 45208 588085 52715460
Abdominal discomfort 40.14 10.58 80 45441 220982 53082563
Vasoplegia syndrome 39.67 10.58 20 45501 1232 53302313
Migraine 39.19 10.58 154 45367 80263 53223282
Drug ineffective for unapproved indication 38.64 10.58 66 45455 20654 53282891
Wound 38.41 10.58 15 45506 91542 53212003
Therapeutic product effect decreased 37.81 10.58 31 45490 125624 53177921
Arrhythmia 37.30 10.58 91 45430 36688 53266857
Large intestine polyp 37.16 10.58 40 45481 8057 53295488
Myocardial stunning 36.45 10.58 11 45510 164 53303381
Bundle branch block right 36.03 10.58 32 45489 5101 53298444
Device pacing issue 34.78 10.58 9 45512 73 53303472
Hyperglycaemia 33.27 10.58 92 45429 39992 53263553
Maternal exposure during pregnancy 33.07 10.58 51 45470 155588 53147957
Arthralgia 32.90 10.58 230 45291 439553 52863992
Hepatic enzyme increased 32.29 10.58 36 45485 126159 53177386
Product coating issue 32.08 10.58 8 45513 55 53303490
Circulatory collapse 31.86 10.58 64 45457 22650 53280895
Ventricular extrasystoles 31.19 10.58 44 45477 11680 53291865
Hyperkalaemia 30.68 10.58 109 45412 54147 53249398
Infection 30.66 10.58 63 45458 172142 53131403
Cardio-respiratory arrest 30.65 10.58 115 45406 58643 53244902
Swelling 29.90 10.58 75 45446 191030 53112515
Pulseless electrical activity 29.36 10.58 34 45487 7420 53296125
Labelled drug-drug interaction medication error 29.14 10.58 41 45480 10858 53292687
Non-cardiogenic pulmonary oedema 29.13 10.58 13 45508 608 53302937
Body temperature decreased 28.46 10.58 51 45470 16576 53286969
Treatment failure 27.34 10.58 42 45479 128361 53175184
Squamous cell carcinoma of the oral cavity 26.37 10.58 10 45511 307 53303238
Hypersensitivity 26.22 10.58 92 45429 210573 53092972
Renal failure 26.19 10.58 182 45339 118270 53185275
Therapeutic product effect incomplete 25.96 10.58 24 45497 91760 53211785
Paradoxical drug reaction 25.90 10.58 22 45499 3303 53300242
Atrioventricular dissociation 25.82 10.58 9 45512 216 53303329
Exposure during pregnancy 25.49 10.58 42 45479 124818 53178727
Pallor 25.21 10.58 62 45459 25120 53278425
Poisoning deliberate 23.62 10.58 33 45488 8680 53294865
Blood pressure decreased 23.58 10.58 110 45411 61759 53241786
Rhythm idioventricular 23.27 10.58 8 45513 184 53303361
Dizziness 23.20 10.58 446 45075 371813 52931732
Respiratory arrest 23.07 10.58 72 45449 33468 53270077
Coma 22.93 10.58 109 45412 61674 53241871
Cardiac failure 22.70 10.58 138 45383 85706 53217839
Accidental overdose 22.69 10.58 54 45467 21425 53282120
Mitral valve incompetence 22.69 10.58 51 45470 19500 53284045
Suspected suicide 22.59 10.58 23 45498 4345 53299200
Discomfort 22.54 10.58 29 45492 95443 53208102
Ventricular fibrillation 22.25 10.58 38 45483 11887 53291658
Clinically isolated syndrome 22.11 10.58 5 45516 21 53303524
Product use issue 21.65 10.58 55 45466 139529 53164016
Hypoperfusion 21.47 10.58 14 45507 1406 53302139
International normalised ratio increased 21.30 10.58 89 45432 47672 53255873
Musculoskeletal stiffness 21.22 10.58 46 45475 123322 53180223
Bradyarrhythmia 21.22 10.58 16 45505 2027 53301518
Acute kidney injury 20.82 10.58 318 45203 253550 53049995
Depressed level of consciousness 20.18 10.58 96 45425 54332 53249213
Duodenal ulcer perforation 20.12 10.58 3 45518 35180 53268365
Off label use 20.10 10.58 283 45238 471929 52831616
Peripheral swelling 19.47 10.58 100 45421 206008 53097537
Melaena 18.64 10.58 61 45460 29068 53274477
Pyrexia 18.46 10.58 238 45283 402955 52900590
Miosis 18.21 10.58 26 45495 6976 53296569
Blood pressure immeasurable 18.21 10.58 12 45509 1227 53302318
Gastric ulcer helicobacter 18.05 10.58 4 45517 15 53303530
Embolic stroke 17.84 10.58 19 45502 3780 53299765
Blood phosphorus decreased 17.83 10.58 20 45501 4217 53299328
Syncope 17.56 10.58 159 45362 111834 53191711
Tricuspid valve disease 17.41 10.58 7 45514 252 53303293
Heart rate decreased 17.38 10.58 70 45451 36877 53266668
Sinus node dysfunction 17.36 10.58 20 45501 4341 53299204
Postresuscitation encephalopathy 17.29 10.58 4 45517 19 53303526
Pulmonary oedema 17.26 10.58 91 45430 53632 53249913
Neutropenia 16.93 10.58 74 45447 159111 53144434
Gastrointestinal disorder 16.81 10.58 32 45489 89972 53213573
Respiratory depression 16.68 10.58 35 45486 12771 53290774
Hypertrophic cardiomyopathy 16.65 10.58 12 45509 1419 53302126
Pupillary reflex impaired 16.58 10.58 14 45507 2085 53301460
Febrile neutropenia 16.54 10.58 41 45480 104895 53198650
Acute lung injury 16.42 10.58 12 45509 1449 53302096
Fatigue 16.34 10.58 487 45034 730019 52573526
Lactic acidosis 16.28 10.58 69 45452 37184 53266361
Distributive shock 16.25 10.58 10 45511 908 53302637
Extrasystoles 16.19 10.58 21 45500 5145 53298400
Conduction disorder 16.05 10.58 12 45509 1500 53302045
Device expulsion 16.03 10.58 3 45518 29810 53273735
Cardiotoxicity 15.98 10.58 25 45496 7274 53296271
Irritable bowel syndrome 15.46 10.58 9 45512 43623 53259922
Gallbladder oedema 15.33 10.58 6 45515 201 53303344
Bundle branch block left 15.32 10.58 24 45497 6989 53296556
Torsade de pointes 15.17 10.58 34 45487 12971 53290574
Exfoliative rash 14.93 10.58 15 45506 2789 53300756
Prinzmetal angina 14.66 10.58 9 45512 814 53302731
Optic ischaemic neuropathy 14.63 10.58 10 45511 1086 53302459
Coma scale abnormal 14.62 10.58 20 45501 5158 53298387
Loss of consciousness 14.42 10.58 155 45366 114057 53189488
Palpitations 14.39 10.58 142 45379 102206 53201339
Electrolyte imbalance 14.36 10.58 42 45479 18842 53284703
Purpura senile 14.24 10.58 8 45513 614 53302931
Neonatal respiratory distress 14.19 10.58 6 45515 246 53303299
Chronic obstructive pulmonary disease 14.18 10.58 95 45426 60978 53242567
Placental calcification 14.05 10.58 3 45518 9 53303536
Tarsal tunnel syndrome 13.96 10.58 8 45513 637 53302908
Hyponatraemic syndrome 13.95 10.58 8 45513 638 53302907
Helicobacter infection 13.93 10.58 8 45513 39061 53264484
Blood pressure inadequately controlled 13.91 10.58 19 45502 4892 53298653
Food interaction 13.87 10.58 8 45513 645 53302900
Malignant neoplasm progression 13.74 10.58 25 45496 71516 53232029
Haemorrhage subcutaneous 13.71 10.58 15 45506 3076 53300469
Neutrophil count decreased 13.69 10.58 13 45508 49085 53254460
Ischaemic stroke 13.66 10.58 40 45481 17953 53285592
Transient ischaemic attack 13.23 10.58 63 45458 35662 53267883
Electrocardiogram PR prolongation 13.16 10.58 8 45513 711 53302834
Salivary gland calculus 13.11 10.58 5 45516 156 53303389
Metastases to retroperitoneum 13.02 10.58 5 45516 159 53303386
Cerebral infarction 12.87 10.58 48 45473 24396 53279149
Snake bite 12.84 10.58 3 45518 15 53303530
Respiratory failure 12.50 10.58 136 45385 100376 53203169
Herbal interaction 12.16 10.58 4 45517 80 53303465
Ventricular tachyarrhythmia 12.16 10.58 4 45517 80 53303465
Ventricular tachycardia 12.09 10.58 38 45483 17724 53285821
Medication error 11.96 10.58 62 45459 36303 53267242
Pulse absent 11.37 10.58 18 45503 5288 53298257
Periorbital oedema 11.35 10.58 18 45503 5297 53298248
Ventricular hypertrophy 11.33 10.58 15 45506 3750 53299795
Arteriospasm coronary 11.29 10.58 15 45506 3762 53299783
Cardioactive drug level decreased 11.25 10.58 4 45517 102 53303443
Loss of personal independence in daily activities 11.22 10.58 27 45494 69788 53233757
Abortion spontaneous 11.18 10.58 14 45507 46621 53256924
Cholestatic liver injury 11.06 10.58 12 45509 2439 53301106
Subendocardial ischaemia 11.00 10.58 4 45517 109 53303436
Hip arthroplasty 10.98 10.58 5 45516 27857 53275688
Intentional product misuse 10.97 10.58 76 45445 49316 53254229
Intentional product use issue 10.90 10.58 29 45492 72465 53231080
Rhabdomyosarcoma 10.90 10.58 4 45517 112 53303433
Cardiac failure acute 10.87 10.58 24 45497 9068 53294477
Product used for unknown indication 10.83 10.58 7 45514 693 53302852
Mixed liver injury 10.82 10.58 15 45506 3918 53299627
Sinusitis 10.75 10.58 92 45429 168472 53135073
Blister 10.74 10.58 33 45488 78720 53224825
Stasis dermatitis 10.72 10.58 7 45514 705 53302840
Malignant neoplasm of ampulla of Vater 10.69 10.58 3 45518 34 53303511
Blood pressure diastolic decreased 10.58 10.58 35 45486 16768 53286777

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 857.57 11.90 669 26542 91848 32394467
Bradycardia 265.68 11.90 313 26898 71249 32415066
Cardiogenic shock 261.82 11.90 181 27030 20481 32465834
Toxicity to various agents 167.70 11.90 422 26789 177619 32308696
Atrioventricular block complete 131.56 11.90 86 27125 8858 32477457
Intentional overdose 117.59 11.90 159 27052 41442 32444873
Shock 116.08 11.90 121 27090 23993 32462322
Hypotension 106.56 11.90 409 26802 215701 32270614
Overdose 80.22 11.90 205 27006 86872 32399443
Nodal rhythm 79.11 11.90 34 27177 1481 32484834
Drug interaction 64.16 11.90 355 26856 217830 32268485
Vasoplegia syndrome 54.84 11.90 26 27185 1428 32484887
Atrioventricular block first degree 53.49 11.90 42 27169 5761 32480554
Sinus bradycardia 51.90 11.90 59 27152 12879 32473436
Supraventricular tachycardia 49.35 11.90 53 27158 10863 32475452
Cerebral artery thrombosis 49.21 11.90 19 27192 626 32485689
Cardiac arrest 47.35 11.90 183 27028 96593 32389722
Medication error 42.03 11.90 71 27140 22464 32463851
Oesophageal ulcer haemorrhage 40.11 11.90 12 27199 177 32486138
Brain scan abnormal 39.63 11.90 17 27194 737 32485578
Suicide attempt 39.35 11.90 94 27117 38150 32448165
Pacemaker generated rhythm 36.00 11.90 9 27202 64 32486251
Cluster headache 35.01 11.90 14 27197 507 32485808
Antiacetylcholine receptor antibody positive 32.36 11.90 8 27203 54 32486261
Poisoning 32.02 11.90 43 27168 11115 32475200
Acute respiratory distress syndrome 31.48 11.90 67 27144 25186 32461129
Areflexia 31.33 11.90 23 27188 2853 32483462
Neutropenia 31.32 11.90 44 27167 142131 32344184
Pyrexia 31.11 11.90 150 27061 319818 32166497
Poisoning deliberate 30.67 11.90 32 27179 6343 32479972
Coma 29.96 11.90 91 27120 42521 32443794
Lactic acidosis 29.84 11.90 78 27133 33458 32452857
Atrial fibrillation 29.71 11.90 183 27028 116521 32369794
Febrile neutropenia 29.45 11.90 34 27177 119532 32366783
Arrhythmia 29.28 11.90 80 27131 35223 32451092
Hemiplegia 27.95 11.90 32 27179 7036 32479279
Prostatic adenoma 27.53 11.90 9 27202 180 32486135
Atrioventricular block 27.51 11.90 33 27178 7622 32478693
Palpitations 27.37 11.90 79 27132 35890 32450425
Compartment syndrome 26.71 11.90 20 27191 2557 32483758
Coma scale abnormal 26.62 11.90 23 27188 3604 32482711
Rhythm idioventricular 26.44 11.90 10 27201 311 32486004
Neuromyopathy 26.18 11.90 14 27197 994 32485321
Normochromic normocytic anaemia 25.85 11.90 24 27187 4131 32482184
Sinoatrial block 25.79 11.90 11 27200 470 32485845
Off label use 25.64 11.90 151 27060 306169 32180146
Diarrhoea 24.96 11.90 191 27020 364611 32121704
Neutrophil count decreased 24.15 11.90 5 27206 47134 32439181
Pseudomonal sepsis 23.85 11.90 20 27191 3009 32483306
Pulse absent 22.92 11.90 26 27185 5660 32480655
Hyperkalaemia 22.79 11.90 117 27094 69633 32416682
Mallory-Weiss syndrome 21.53 11.90 14 27197 1428 32484887
Anuria 21.35 11.90 35 27176 10802 32475513
Ischaemic stroke 21.17 11.90 46 27165 17530 32468785
Pneumonia 20.26 11.90 195 27016 355057 32131258
Arterial disorder 20.14 11.90 13 27198 1309 32485006
Foetal exposure during pregnancy 19.91 11.90 5 27206 41296 32445019
Superinfection 19.81 11.90 15 27196 1949 32484366
Xanthelasma 19.66 11.90 6 27205 95 32486220
Non-cardiogenic pulmonary oedema 19.19 11.90 10 27201 673 32485642
Neck injury 18.52 11.90 12 27199 1216 32485099
Fear of weight gain 18.13 11.90 4 27207 15 32486300
Infection 17.87 11.90 27 27184 84688 32401627
Cerebral haematoma 17.72 11.90 21 27190 4790 32481525
Cardiorenal syndrome 17.69 11.90 10 27201 792 32485523
Tobacco abuse 17.57 11.90 8 27203 400 32485915
Cerebrovascular accident 17.52 11.90 128 27083 86192 32400123
Drug ineffective 17.30 11.90 222 26989 383255 32103060
Adrenal cortex necrosis 17.20 11.90 4 27207 20 32486295
Pallor 16.20 11.90 49 27162 22832 32463483
Cardiac failure congestive 16.18 11.90 124 27087 84728 32401587
Disease progression 16.18 11.90 30 27181 86832 32399483
Acidosis 16.16 11.90 31 27180 10815 32475500
Plasma cell myeloma 15.72 11.90 15 27196 57599 32428716
Malignant neoplasm progression 15.62 11.90 26 27185 78470 32407845
Rheumatoid arthritis 15.50 11.90 9 27202 44535 32441780
Thrombocytopenia 15.26 11.90 68 27143 148231 32338084
Antineutrophil cytoplasmic antibody increased 15.17 11.90 4 27207 36 32486279
Myofascial pain syndrome 15.14 11.90 7 27204 363 32485952
Acute kidney injury 15.05 11.90 336 26875 293132 32193183
Cerebral infarction 14.96 11.90 54 27157 27560 32458755
Prothrombin time ratio decreased 14.75 11.90 7 27204 385 32485930
Vascular resistance systemic decreased 14.68 11.90 5 27206 114 32486201
Intensive care 14.65 11.90 7 27204 391 32485924
Nodal arrhythmia 14.51 11.90 9 27202 845 32485470
Benign prostatic hyperplasia 14.48 11.90 32 27179 12332 32473983
Pancytopenia 14.09 11.90 35 27176 91200 32395115
Erythromelalgia 14.05 11.90 4 27207 49 32486266
Bezoar 13.88 11.90 9 27202 913 32485402
Rhabdomyolysis 13.79 11.90 100 27111 67165 32419150
Bundle branch block left 13.23 11.90 20 27191 5759 32480556
Lip discolouration 13.20 11.90 5 27206 156 32486159
Lividity 13.09 11.90 5 27206 160 32486155
Hospitalisation 13.07 11.90 13 27198 48958 32437357
Heart rate abnormal 12.72 11.90 11 27200 1726 32484589
Pulmonary oedema 12.67 11.90 74 27137 46193 32440122
Loss of consciousness 12.64 11.90 115 27096 82592 32403723
Atrial tachycardia 12.44 11.90 12 27199 2165 32484150
Metabolic acidosis 12.41 11.90 67 27144 40632 32445683
Carpal tunnel syndrome 12.39 11.90 17 27194 4484 32481831
Rebound tachycardia 12.30 11.90 3 27208 19 32486296
Periorbital oedema 12.27 11.90 15 27196 3533 32482782
Sinus node dysfunction 12.24 11.90 16 27195 4028 32482287
Faecal calprotectin abnormal 12.13 11.90 5 27206 196 32486119
Alcohol withdrawal syndrome 12.06 11.90 10 27201 1481 32484834
Burns second degree 11.97 11.90 6 27205 372 32485943

Pharmacologic Action:

SourceCodeDescription
ATC C08DA01 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
Phenylalkylamine derivatives
ATC C08DA51 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
Phenylalkylamine derivatives
ATC C09BB10 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175566 Calcium Channel Blocker
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:62872 aldehyde oxidase (EC 1.2.3.1) inhibitors
CHEBI has role CHEBI:77255 lethal toxin inhibitor
CHEBI has role CHEBI:77745 meprin inhibitor
CHEBI has role CHEBI:77747 phospholipid-translocating ATPase (EC 3.6.3.1) inhibitor
CHEBI has role CHEBI:77748 steroid-transporting ATPase inhibitors
CHEBI has role CHEBI:78298 environmental contaminants
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Atrial fibrillation indication 49436004 DOID:0060224
Paroxysmal supraventricular tachycardia indication 67198005
Prinzmetal angina indication 87343002
Angina pectoris indication 194828000
Acute coronary syndrome indication 394659003
Prevention of Paroxysmal Supraventricular Tachycardia indication
Cardioversion of Atrial Fibrillation indication
Diastolic heart failure off-label use 418304008 DOID:9775
Cluster Headache Prevention off-label use
Hyperkalemia contraindication 14140009
Ventricular tachycardia contraindication 25569003
Complete atrioventricular block contraindication 27885002
Acute cerebrovascular insufficiency contraindication 29322000
Sick sinus syndrome contraindication 36083008 DOID:13884
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Low cardiac output syndrome contraindication 44088000
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Lown-Ganong-Levine syndrome contraindication 55475008 DOID:13087
Aortic valve stenosis contraindication 60573004 DOID:1712
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Transplantation contraindication 77465005
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Second degree atrioventricular block contraindication 195042002
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
First Degree Atrioventricular Heart Block contraindication
Neuromuscular Transmission Deficiency contraindication
Hemodialysis with High-Flux Membrane contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.91 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel BLOCKER UNKNOWN IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER IC50 6 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 8 CHEMBL
Cytochrome P450 3A4 Enzyme INHIBITOR Ki 6.22 IUPHAR
Multidrug resistance protein 1 Transporter Ki 6.52 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.90 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.76 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.85 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 6.98 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.81 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.20 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.59 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 5.46 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 6.07 DRUG MATRIX
Multidrug resistance-associated protein 1 Transporter Ki 4.88 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter EC50 4.43 CHEMBL
Carbonic anhydrase 1 Enzyme WOMBAT-PK
G protein-activated inward rectifier potassium channel 2 Ion channel WOMBAT-PK
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel BLOCKER Ki 4.49 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 10 Ion channel BLOCKER IC50 4.30 IUPHAR
Potassium voltage-gated channel subfamily A member 3 Ion channel IC50 5.10 CHEMBL
Potassium voltage-gated channel subfamily C member 2 Ion channel EC50 4.90 WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 5.17 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 4.35 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 7 Ion channel Kd 4.80 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 4.07 WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.48 CHEMBL
Equilibrative nucleoside transporter 4 Transporter INHIBITOR Ki 4.73 IUPHAR
Two pore calcium channel protein 1 Ion channel BLOCKER IC50 4.64 IUPHAR
Sodium channel protein type 5 subunit alpha Ion channel WOMBAT-PK
Two pore calcium channel protein 2 Ion channel BLOCKER IC50 5 IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 6.66 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.03 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.76 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 5.68 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.52 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 6 CHEMBL
Translocator protein Membrane receptor IC50 8.85 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 7.41 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel Ki 7.24 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR EC50 4.51 CHEMBL
Voltage-gated L-type calcium channel Ion channel IC50 8.43 CHEMBL
Chloroquine resistance transporter Transporter IC50 4.52 CHEMBL
Potassium voltage-gated channel subfamily C member 2 Ion channel BLOCKER EC50 4.90 IUPHAR

External reference:

IDSource
4019969 VUID
N0000148054 NUI
D00619 KEGG_DRUG
152-11-4 SECONDARY_CAS_RN
4018128 VANDF
4019969 VANDF
C0042523 UMLSCUI
CHEBI:9948 CHEBI
CHEMBL6966 ChEMBL_ID
CHEMBL1280 ChEMBL_ID
D014700 MESH_DESCRIPTOR_UI
DB00661 DRUGBANK_ID
2406 IUPHAR_LIGAND_ID
2122 INN_ID
CJ0O37KU29 UNII
2520 PUBCHEM_CID
11170 RXNORM
5670 MMSL
757 MMSL
d00048 MMSL
000709 NDDF
004515 NDDF
14340003 SNOMEDCT_US
372754009 SNOMEDCT_US
47898004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-1891 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-1901 TABLET, FILM COATED, EXTENDED RELEASE 120 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-1911 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-2712 TABLET, FILM COATED, EXTENDED RELEASE 120 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-2818 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-2924 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 23 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6320 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 16 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6380 CAPSULE, EXTENDED RELEASE 180 mg ORAL ANDA 16 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6440 CAPSULE, EXTENDED RELEASE 240 mg ORAL ANDA 16 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9966 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 11 sections
VERAPAMIL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9967 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9968 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1144 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 17 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1144 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 17 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-4011 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 17 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-9633 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 17 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0343 TABLET, FILM COATED 80 mg ORAL ANDA 20 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0345 TABLET, FILM COATED 120 mg ORAL ANDA 20 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0404 TABLET, FILM COATED 40 mg ORAL ANDA 20 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2880 CAPSULE, DELAYED RELEASE PELLETS 120 mg ORAL NDA 24 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2882 CAPSULE, DELAYED RELEASE PELLETS 180 mg ORAL NDA 24 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2884 CAPSULE, DELAYED RELEASE PELLETS 240 mg ORAL NDA 24 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2886 CAPSULE, DELAYED RELEASE PELLETS 360 mg ORAL NDA 24 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-3588 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL ANDA 23 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-3589 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL ANDA 23 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7618 TABLET, FILM COATED 80 mg ORAL ANDA 19 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7619 TABLET, FILM COATED 120 mg ORAL ANDA 19 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-2920 TABLET, FILM COATED 80 mg ORAL ANDA 20 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-2924 TABLET, FILM COATED 120 mg ORAL ANDA 20 sections
verapamil hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-035 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL ANDA 21 sections